Table 2 Clinical outcome of patients with clonal or subclonal RAS pathway mutations

From: RAS pathway mutations as a predictive biomarker for treatment adaptation in pediatric B-cell precursor acute lymphoblastic leukemia

Mutation status

n

EFS

CIR

  

5-year EFS in % (s.e.)

Cox’s hazard ratio a

Log-rank

5-year CIR in % (s.e.)

Gray’s test

    

Pcl

 

Pcl

ALL10 b

 Wild type

135

92 (2)

  

8 (2)

 

 Mutated

109

86 (3)

  

11 (3)

 

ALL10 b

 Wild type

135

92 (2)

  

8 (2)

 

 Subclonal

59

88 (4)

  

11 (4)

 

 Clonal

50

84 (5)

  

10 (4)

 

 SR

Wild type

49

96 (3)

  

4 (3)

 

Subclonal

15

93 (6)

  

7 (7)

 

Clonal

10

69 (15)

4.57 (CI: 1.02-20.5)

0.027

21 (14)

 

 MR

Wild type

75

88 (4)

  

12 (4)

 

Subclonal

42

85 (6)

  

12 (5)

 

Clonal

31

97 (3)

 

0.058

0

0.01

 HR

Wild type

11

100

  

0

 

Subclonal

2

N/Ac

  

N/Ac

 

Clonal

9

56 (16.6)

 

0.015

33 (17)

0.044

  1. Abbreviations: CIR, cumulative incidence of relapse and non-response; EFS, event-free survival; HR, high risk; MR, medium risk; n/a, not applicable; Pcl, P-value for comparison clonal vs wild-type cases; SR, standard risk. Only P-values <0.1 are shown.
  2. aOnly shown if significantly different, reference group: wild-type cases.
  3. bAll tests stratified for risk arms of this protocol (SR, MR and HR).
  4. c5-year follow-up only reached by one patient. Values of P< 0.05 are printed in bold.
Back to article page